Q3 2025 National Research Corp Earnings Call Transcript
Key Points
- Revenue reached nearly $35 million with an 11% year-over-year growth in adjusted EBITDA.
- Total recurring contract value (TRCV) rose 8% year-over-year to $142 million, marking the strongest growth since 2020.
- Secured multiple significant deals, including a TRCV expansion over $1 million with a TOP50 health system.
- Customer retention has strengthened, with TRCV losses and down sells reduced by nearly 50%.
- Net retention rate reached its highest level since 2020, driven by strong cross-sell and upsell activities.
- Operating expenses were lower due to reduced compensation and marketing expenses, which may return in Q4.
- Revenue growth was only 2% sequentially, indicating potential challenges in accelerating growth.
- The company repurchased shares, which reduced the share count but also used $9.3 million of cash.
- The healthcare market is facing challenges such as regulatory complexity and financial pressure.
- The company is undergoing a transition with a new CFO, which may pose integration challenges.
Good afternoon. Thank you for attending the NRC Health Third quarter 2025 earnings call. My name is Cameron, and I'll be your moderator for today.
I would now like to pass the conference over to your host for today's call. You may proceed.
Thank you, operator. Welcome to NRC Health earnings conference call for the third quarter ended September 30th, 2025. I want to first let you know that we posted our earnings press release to the investor relations section on our website. On the call today, we have NRC Health CEO Trent Green and our new CFO Shane Harrison.
Before getting started, I'd like to emphasize that this call will include statements related to the expected future results of our company, which are therefore forward-looking statements. Our actual results may differ materially from our expectations due to a number of risks and uncertainties, including those described in our earnings relief and other SEC filings.
Today's remarks will include references to non-GAAP
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
